Vilanterol

Vilanterol
Names
Trade namesWith fluticasone: Breo Ellipta, Relvar Ellipta
With umeclidinium: Anoro Ellipta
With both: Trelegy Ellipta
IUPAC name
  • 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
Clinical data
Main usesCOPD, asthma[1][2]
Side effectsNose and throat irritation, thrush, chest pain[2]
Pregnancy
category
  • AU: B3
    Routes of
    use    		By inhalation
    External links
    AHFS/Drugs.comMonograph
    US NLMVilanterol
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Chemical and physical data
    FormulaC24H33Cl2NO5
    Molar mass486.43 g·mol−1
    3D model (JSmol)
    SMILES
    • c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl
    InChI
    • InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
    • Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N

    Vilanterol is a medication primarily used to treat chronic obstructive pulmonary disease (COPD).[2] It may also be used to prevent worsening in asthma.[1] It is inhaled in combination with other medications.[1]

    Common side effects include nose and throat irritation, thrush, and chest pain.[2] Other side effects may include anaphylaxis and bronchospasm.[2] It is a long-acting β2 adrenoreceptor agonist (LABA).[2]

    Vilanterol in combination with fluticasone was approved for medical use in the United States in 2013.[3] It is also avaliable as umeclidinium/vilanterol and fluticasone/umeclidinium/vilanterol.[2][1] In the United Kingdom a month of medication costs the NHS about £20 to £45 as of 2021.[1] In the United States this amount costs about 190 USD.[4]

    Medical uses

    Combinations

    Vilanterol is available in following combinations:

    Dosage

    It is used by inhalation once per day.[1]

    See also

    • Salmeterol—a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.

    References

    1. 1 2 3 4 5 6 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 279. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
    2. 1 2 3 4 5 6 7 "Vilanterol Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 15 September 2021.
    3. ↑ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". web.archive.org. 18 January 2017. Archived from the original on 18 January 2017. Retrieved 15 September 2021.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
    4. ↑ "Breo Ellipta Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 25 April 2020. Retrieved 15 September 2021.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.